From: Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study
Visits | Baseline day 1 | Baseline day 2 | Month 3a ± 21 days | Month 6b  ± 21 days | Month 12  ± 21 days |
---|---|---|---|---|---|
Informed consent | X | Â | Â | Â | Â |
Demographic information | X | Â | Â | Â | Â |
Medical and surgical history | X | Â | Â | Â | Â |
Inclusion exclusion | X | Â | Â | Â | Â |
Vital signs | X | X | X | X | X |
Physical exam | Xc | Xc | X | X | X |
Pregnancy testd | X | Â | X | X | X |
10 Meter walk | X | Â | Â | Â | Â |
100Â m timed | X | X | X | X | X |
NSAD | X | X | X | X | X |
4 stair climb | X | X | X | X | X |
Timed Up and Go (TUG) | X | X | X | X | X |
Handheld dynamometry | X | X | X | X | X |
Performance Upper Limb PUL 2.0 | X | X | X | X | X |
9 hole peg test | X | X | X | X | X |
Spirometry | X | X | X | X | X |
Concomitant meds | X | X | X | X | X |
Domain delta questionnaire | Â | X | X | X | X |
Patient reported outcome measures | Xc | Xc | X | X | X |
Urine biomarkers | Â | X | Â | X | X |
Blood biomarkers | Â | X | X | X | X |
Prior muscle biopsy acquired (if performed) | X | Â | Â | Â | Â |
Review adverse events | Â | X | X | X | X |